PURE Bioscience (PURE) Lowered to “Sell” at ValuEngine

ValuEngine downgraded shares of PURE Bioscience (OTCMKTS:PURE) from a hold rating to a sell rating in a research note released on Tuesday.

PURE Bioscience (PURE) opened at 1.00 on Tuesday. PURE Bioscience has a 1-year low of $0.75 and a 1-year high of $1.36. The company’s market capitalization is $62.71 million. The company has a 50-day moving average of $1.18 and a 200-day moving average of $1.07.

ILLEGAL ACTIVITY WARNING: This report was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.thestockobserver.com/2017/09/13/pure-bioscience-pure-lowered-to-sell-at-valuengine.html.

PURE Bioscience Company Profile

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply